OPRX - OptimizeRx Corp. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

OPRX

OPTIMIZERX CORP.

NASDAQ

$8.28

▼ DOWN 1.19% (-0.10)

KEY STATISTICS

Market Cap$156.88 M

52w High$22.25

52w Low$4.54

Dividend Yield—

Frequency—

P/E7.60

Volume123.20K

Shares Out.18.77M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Stephen L. Silvestro

COMPENSATION 2026

Salary$500,000

Stock Awards$752,184

Incentive Plan Pay$627,623

All Other Comp.$3,600

Total$2,717,717

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 28, 2007

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

133

PRICE TARGET

Target High$12.00

Target Low$7.00

Target Median$11.00

Target Consensus$10.25

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$21.19M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2018-05-14	Reverse	1:3
2008-04-17	Reverse	1:1000
2008-04-02	Reverse	1:1000
2006-12-18	Forward	6:1

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

43.39%

HOLDERS

198

TOP 8 OF 198 · RANKED BY POSITION SIZE

Whetstone Capital Advisors, LLC

Royce & Associates LP

1.1M sh

$6.23M

Parkman Healthcare Partners LLC

729.4K sh

$4.58M

Kennedy Capital Management LLC

674.9K sh

$13.84M

Rice Hall James & Associates, LLC

633.8K sh

$3.63M

PRICE

$8.28 ▼ DOWN 1.19% (−$0.10)

OVERLAYS

About OptimizeRx Corp.

https://www.optimizerx.com ↗

OptimizeRx Corporation provides digital health solutions—including patient support, brand messaging, and adherence platforms—for life sciences, healthcare providers, and patients to improve medication access and engagement.

INDUSTRY

Medical - Healthcare Information Services

A SERVICE OPTIMIZERX CORP. IS KNOWN FOR

Dynamic Audience Activation Platform (DAAP)

OptimizeRx's AI-driven platform enables pharmaceutical companies to deliver targeted, data-driven marketing messages to healthcare providers and patients via EHR integration, enhancing communication and revenue through predictive analytics and mac...

COMPETITORS

COMPETITOR

OptimizeRx in 2025

SENTIMENT: + POSITIVE

EARNINGS · AUGUST 2025

OptimizeRx Crushes Q2 2025 Earnings Expectations, Sparking Major Stock Surge

OptimizeRx reported a massive 55% year-over-year revenue increase to $29.2 million for the second quarter of 2025, significantly outperforming analyst expectations. The company posted a non-GAAP EPS of $0.24, an extraordinary 1100% surprise over the forecasted $0.02, leading to a substantial increase in its full-year guidance and a significant surge in its stock price.

LEADERSHIP STRATEGY · AUGUST 2025 · IN PROGRESS

OptimizeRx Reorganizes Leadership to Accelerate 'Rule of 40' Strategy for Profitable Growth

OptimizeRx initiated a significant leadership reorganization to align its management structure with its strategic goal of achieving the 'Rule of 40,' a key metric for software companies that balances revenue growth and profitability. This strategic move, led by CEO Steve Silvestro, aims to enhance operational excellence and transition the company towards a more predictable, recurring revenue model.